NCT03420963 2026-03-03
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
Clinical Trials
20 trialsNCT06885697 2026-02-17
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06598371 2026-02-11
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06556108 2026-01-20
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
Phase 1/2 Completed
NCT02870907 2026-01-07
RB SFCE 09
Institut Curie
Phase 2 Active not recruiting
NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT05521984 2025-12-08
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
Phase 1 Recruiting
NCT06066424 2025-10-14
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT02414269 2025-10-08
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT00186888 2025-09-04
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
St. Jude Children's Research Hospital
Phase 3 Completed
NCT03907852 2025-08-27
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
Phase 1/2 Active not recruiting
NCT05451849 2025-08-27
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
Phase 1/2 Active not recruiting
NCT05279300 2025-08-11
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
Phase 1 Recruiting
NCT02498912 2025-07-31
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04577326 2025-07-25
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05275777 2025-07-25
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT05881525 2025-07-16
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
TCRCure Biopharma Ltd.
Phase 1 Recruiting
NCT03935893 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Recruiting
NCT07010523 2025-06-08
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang University
Phase NA Recruiting